Anti-CD20 monoclonal antibodies: reviewing a revolution
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2018-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|